ArticleFrontiers in immunology2026
An anoikis-related four-gene prognostic signature and functional characterization of ANXA5 in laryngeal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell carcinoma (LSCC) remains one of the most lethal malignancies of the head and neck region. Tumor metastasis, the primary cause of treatment failure, is intimately linked to the evasion of anoikis. Yet the molecular drivers of this process in LSCC are incompletely understood. This study systematically investigates the prognostic and functional landscape of anoikis-related genes (ARGs) in LSCC, with an emphasis on their interplay with the tumor immune microenvironment and therapeutic vulnerability. Methods: RNA-sequencing profiles and clinical data from the TCGA-LSCC cohort were analyzed, and candidate anoikis-related genes (ARGs) were curated from the GeneCards and Harmonizome databases. Differentially expressed and prognosis-associated ARGs were screened using limma and univariate Cox regression. A four-gene prognostic signature was constructed in the training set using LASSO-Cox and multivariate Cox regression and internally evaluated in the testing set. The resulting anoikis-related risk score was assessed in relation to survival, clinicopathological variables, immune characteristics, pathway enrichment, and predicted drug response. Single-cell RNA-sequencing data were used to characterize the cellular distribution of the signature genes. ANXA5 was prioritized for experimental evaluation because it had the largest positive model coefficient among the risk-associated genes, showed tumor-associated dysregulation, and had biological relevance to anoikis-related processes. Its effects were examined in TU686 cells using expression, cell-viability, EMT-marker, apoptosis, and wound-healing assays. Results: The ARG-based signature effectively stratified LSCC patients into high- and low-risk groups with significantly different overall survival (p < 0.001). High anoikis-related risk score correlated with an immunosuppressive TME, suggesting a permissive milieu for immune evasion. Drug sensitivity analysis revealed that high-risk patients were more responsive to certain tyrosine kinase inhibitors but resistant to conventional chemotherapeutics, highlighting subtype-specific therapeutic opportunities. Among the ARGs, Conclusion: The four-gene anoikis-related signature showed prognostic stratification within the TCGA-LSCC cohort and was associated with differences in the tumor immune microenvironment. ANXA5 may represent a candidate prognostic biomarker and a biologically relevant gene for further mechanistic investigation; however, external validation and additional functional studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.